A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Atrial fibrillation (AF)-related stroke accounts for 20% of ischemic strokes. Rivaroxaban use in AF patients for preventing stroke and systemic embolism was approved in 2013 in Korea. This study was to investigate the safety and effectiveness of rivaroxaban use in Korean patients with non-valvular AF in a real-world setting. Methods: This was an analysis of the Korean patients in Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation in Asia-Pacific (XANAP), which was a prospective, observational cohort study including patients with non-valvular AF starting rivaroxaban treatment to prevent stroke or non-central nervous system systemic embolism (non-CNS SE), conducted in 10 Asian countries. Results: A total of 844 patients were enrolled in the Korean portion of the XANAP study. In XANAP Korea, the mean age was 70.1 years and 62.6% were males. The mean CHADS2 score was 2.5 and the mean CHA2DS2-VASc score was 3.8. 47% of the patients had experienced prior stroke or non-CNS SE or transient ischemic attack. 73.6% of the patients had CHADS2 score ≥ 2. Incidence proportions of 0.8% of the patients (1.1 per 100 patient-years) developed adjudicated treatment-emergent major bleeding. Death was observed in 1.2% of the patients. The incidence of non-major bleeding as well as thromboembolic event were 8.4% (11.6 per 100 patient-years) and 1.5% (2.0 per 100 patient-years), respectively. Conclusions: This study reaffirmed the consistent safety profile of rivaroxaban. We found consistent results with overall XANAP population for rivaroxaban in terms of safety in non-valvular AF patients for the prevention of stroke and non- CNS SE.
Abstract
Background/Aims: Atrial fibrillation (AF)-related stroke accounts for 20% of ischemic strokes. Rivaroxaban use in AF patients for preventing stroke and systemic embolism was approved in 2013 in Korea. This study was to investigate the safety and effectiveness of rivaroxaban use in Korean patients with non-valvular AF in a real-world setting. Methods: This was an analysis of the Korean patients in Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation in Asia-Pacific (XANAP), which was a prospective, observational cohort study including patients with non-valvular AF starting rivaroxaban treatment to prevent stroke or non-central nervous system systemic embolism (non-CNS SE), conducted in 10 Asian countries. Results: A total of 844 patients were enrolled in the Korean portion of the XANAP study. In XANAP Korea, the mean age was 70.1 years and 62.6% were males. The mean CHADS2 score was 2.5 and the mean CHA2DS2-VASc score was 3.8. 47% of the patients had experienced prior stroke or non-CNS SE or transient ischemic attack. 73.6% of the patients had CHADS2 score ≥ 2. Incidence proportions of 0.8% of the patients (1.1 per 100 patient-years) developed adjudicated treatment-emergent major bleeding. Death was observed in 1.2% of the patients. The incidence of non-major bleeding as well as thromboembolic event were 8.4% (11.6 per 100 patient-years) and 1.5% (2.0 per 100 patient-years), respectively. Conclusions: This study reaffirmed the consistent safety profile of rivaroxaban. We found consistent results with overall XANAP population for rivaroxaban in terms of safety in non-valvular AF patients for the prevention of stroke and non- CNS SE.
참고문헌 (15)
- Wang KL, "Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation : meta-analysis", Stroke, 46, pp.2555~2561 (2015)
- Yan-Guang Li, "Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients", Korean Circulation Journal, 48(8), pp.665~684 (2018), 대한심장학회[DOI]
- Sabir I, "Oral anticoagulants for Asian patients with atrial fibrillation", Nat Rev Cardiol, 11, pp.290~303 (2014)
- Kim D, "10-Year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population", Am Heart J, 202, pp.20~26 (2018)
- Lee SR, "Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population", Int J Cardiol, 236, pp.226~231 (2017)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Wong KS, "Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial", Stroke, 45, pp.1739~1747 (2014)
- Camm AJ, "XANTUS : a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation", Eur Heart J, 37, pp.1145~1153 (2016)
- 차명진, "심방세동 환자에서의 뇌졸중 예방", International Journal of Arrhythmia, 18(3), pp.137~142 (2017), 대한부정맥학회[DOI]
- Kim YH, "XANAP : A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia", J Arrhythm, 34, pp.418~427 (2018)
- "Xarelto (rivaroxaban) summary of product characteristics" (2018)[URL]
- Keun-Sik Hong, "Stroke Statistics in Korea: Part I. Epidemiology and Risk Factors: A Report from the Korean Stroke Society and Clinical Research Center for Stroke", 대한뇌졸중영문학회지, 15(1), pp.2~20 (2013), 대한뇌졸중학회[DOI]
- Marini C, "Contribution of atrial fibrillation to incidence and outcome of ischemic stroke : results from a population-based study", Stroke, 36, pp.1115~1119 (2005)
- 이소령, "Prevalence of Atrial Fibrillation in Korean Population", International Journal of Arrhythmia, 18(4), pp.195~204 (2017), 대한부정맥학회[DOI]
- Nallamothu BK, "Beyond the randomized clinical trial : the role of effectiveness studies in evaluating cardiovascular therapies", Circulation, 118, pp.1294~1303 (2008)